Watching for the Patient With AF: Latest Advances and Technologies

Slides:



Advertisements
Similar presentations
PROTECT-AF (LAA Closure with Watchman vs Warfarin in AF and Stroke) A long-term (45-month) follow-up analysis of device therapy with Watchman vs warfarin.
Advertisements

Improving Stroke Prevention in Patients With Atrial Fibrillation.
Post-FDA Approval, Initial US Clinical Experience with Watchman Left Atrial Appendage Closure for Stroke Prevention in Atrial Fibrillation Vivek Y. Reddy.
Rachel Neubrander, PhD Division of Cardiovascular Devices
LAAC: What Does the Post Marketing Data Tell Us?
Post-FDA Approval, Initial US Clinical Experience with Watchman Left Atrial Appendage Closure for Stroke Prevention in Atrial Fibrillation Vivek Y. Reddy.
LAA Closure: Lessons from the Pivotal Studies & Three Advisory Panels
Addressing the Challenges in Primary and Secondary Stroke Prevention
David R. Holmes, Jr., M.D. Mayo Clinic, Rochester
Sameer Gafoor, MD Swedish Medical Center, Seattle WA
Covering the Bases in Cardioversion
Silent No More:.
Burden of Atrial Fibrillation The Percentage of Strokes Attributable to AF Increases With Age.
Anticoagulant Safety Remains a Problem Emergency Hospitalizations for Adverse Drug Events.
The Ever-Expanding Patient Pool for TAVR:
Atrial Fibrillation and PCI
Advances in Managing Inhibitors in Patients With Hemophilia A
Updates in Anticoagulation: What Did We Learn From ESC 2017?
US Guidelines US Guidelines Low-risk Patients.
NOACs, AF, and PCI: What Do the Latest Data Suggest?
Achieving Long-Term Protection Post-MI
When Is Adding Aspirin to NOACs Worth the Risk?
Barriers to Oral Anticoagulant Use for Stroke Prevention in AF
Access to NOAC Therapy:
Introduction ESC Annual Meeting in Review: NOACs and NVAF: Real-World Data, Guidelines, and More.
Emergency Management of NOAC Bleeding
Anticoagulation Highlights From the American Heart Association Meeting 2017.
New Perspectives in AF and PCI: Implications for the Practicing Physician.
New Perspectives in CAD and PAD: Weighing the Latest Evidence
Oral Anticoagulants in AFa,b A Brief History.
Global Burden of VTE. Preventing Thrombosis During and Post-Hospitalization: New Paradigms in Clinical Care.
Surveying the Safety of NOACs in the Real World
Selecting NOACs for High-Risk Patients
Antiplatelet Therapy and Secondary Prevention
Clarifying Optimal Patient Selection for Long-Term DAPT Post-MI
NOAC Use in AF: REAL-WORLD Studies WITH REAL RESULTS
Revealing Characteristics of Patients at High Risk for Developing Atrial Fibrillation.
The Essentials for Secondary Stroke Prevention
Anticoagulation Therapy in Patients Post-TAVR
Stroke and AF.
Assessing the Risk for Stroke in Patients With Atrial Fibrillation
Applying Real-World Evidence in Atrial Fibrillation Into Clinical Care:
Efficacy and Safety of Edoxaban in Patients With AF and HF
Access to NOAC Therapy:
Antithrombotic Protection in CAD and HF
TAVR and the Risk of Thrombosis
Understanding PAD.
Adherence in SPAF: Measures to Improve Care
Left atrial appendage closure: A new technique for clinical practice
What Anticoagulant Registries Are Revealing
VTE in Cancer.
Dos and Don’ts for High-Risk Elderly Patients With AF
Atrial Fibrillation.
Anticoagulation and Thrombosis Management
Identifying High-Risk AF Patients
Definition of Elderly. Advanced Age and CV Risk: To Start or Not to Start a Statin in Older Patients?
Factor Xa Inhibitors in PAD
CAD/PAD in Primary Care
Cancer-Associated Thrombosis
Improving Outcomes in AF: Do the NOACs Hold Their Promise In The Real World?
Antithrombotic Therapy in PAD
The Challenge of AF and PCI: Practical Strategies to Improve Outcomes
Factor Xa Inhibitors in Coronary Artery Disease
Improving Adherence to Antiplatelet Therapy After an ACS Event
5 Good Minutes on Atrial Fibrillation-related Stroke
Left Atrial Appendage Occlusion for The Unmet Clinical Needs of Stroke Prevention in Nonvalvular Atrial Fibrillation  David R. Holmes, MD, Mohamad Alkhouli,
Empowering Patients and Prescribers to Improve Treatment Adherence in Schizophrenia.
Gianluigi Savarese et al. JCHF 2016;4:
Extraordinary Cases in Stroke Prevention
What's New in NOACs in AF?.
Presentation transcript:

Watching for the Patient With AF: Latest Advances and Technologies

Program Goals

Patient Interview

Risk of Stroke for Patients With AF

Challenges Associated With Anticoagulant Therapy

Patients at Risk for Bleeding

Stroke Risk From AF

PROTECT AF Study (N = 800)

The PREVAIL Trial

WATCHMAN: Meta-Analysis

Procedural Events

EWOLUTION Registry

Post-Approval US Experience

PROTECT and PREVAIL: Pooled, Patient-Level Analysis

PROTECT and PREVAIL: Pooled, Patient-Level Analysis (cont)

Other Devices

ASAP-TOO

FDA Approval

CMS Requirements

Talking to Patient

Procedure Team

Summary

Summary (cont)